Parkinson Progression Marker Initiative Online (PPMI Online)
NCT ID: NCT05065060
Last Updated: 2024-11-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
500000 participants
OBSERVATIONAL
2021-07-28
2041-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PPMI Online is part of the broader Parkinson Progression Marker Initiative aimed at identifying markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort
NCT04477785
Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression
NCT01141023
Parkinson's Foundation Surveys
NCT05066763
Cohort Study to Identify Predictor Factors of Onset and Progression of Parkinson's Disease
NCT02305147
Cognitive Testing Online in Parkinson's Disease
NCT05025254
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Observation
Observation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or female age 18 years or older.
* Has received a diagnosis of Parkinson's disease
Participants without PD:
* Male or female age 18 years or older.
* Has not received a diagnosis of Parkinson's disease
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Michael J. Fox Foundation for Parkinson's Research
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Caroline M Tanner
Protocol Co- Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Caroline Tanner, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University of California, San Francisco
Kenneth L Marek, MD
Role: PRINCIPAL_INVESTIGATOR
Institute for Neurodegenerative Disorders
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UCSF Movement Disorders and Neuromodulation Center (MDNC)
San Francisco, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
UCSF
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Pierz KA, Aamodt W, Gochanour C, Kurth R, Brumm MC, Coffey CS, Heathers LE, Totten M, Doty RL, Marek K, Siderowf A; Parkinson's Progression Markers Initiative. Percentile scores for the revised University of Pennsylvania Smell Identification Test for 16,972 individuals 60 years of age and older. NPJ Parkinsons Dis. 2025 Oct 1;11(1):280. doi: 10.1038/s41531-025-01095-9.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PPMI-007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.